Among patients with obesity and compensated cirrhosis, bariatric surgery may significantly lower the risk of developing serious liver disease complications, according to a recent study by Cleveland ...

Bariatric surgery significantly reduced long-term risk for decompensation and adverse outcomes in patients with obesity and compensated metabolic dysfunction-associated steatohepatitis (MASH)-related ...

Please provide your email address to receive an email when new articles are posted on . Bariatric surgery was cost-effective over 10 years at a threshold of $100,000 per QALY among patients with ...

MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic dysfunction-associated steatohepatitis (MASH): Moderator Sobia Laique, MD, of the Cleveland ...

Please provide your email address to receive an email when new articles are posted on . Metabolic surgery reduced major adverse liver outcomes in patients with MASH with compensated cirrhosis by 72%.

MASLD/MASH represents a growing clinical and economic burden, with MASH conferring heightened risks of advanced fibrosis, cirrhosis, hepatocellular carcinoma, and liver-related mortality. Noninvasive ...

(HealthDay News) — For patients with compensated metabolic dysfunction-associated steatohepatitis (MASH)-related cirrhosis and obesity, metabolic surgery is associated with a lower risk for incident ...

MRI-PDFF is a validated, noninvasive tool for quantifying hepatic steatosis, increasingly used in MASH clinical trials. A network meta-analysis compared 41 pharmacologic interventions, revealing ...

Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinflammatory diseases, today announced ...

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) compared with ...